Longitudinal Changes in Whole-Body MRI Phenotypes and Disease Associations
NCT07924891, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Longitudinal Changes in Whole-Body MRI Phenotypes and Disease Associations | ClinicalTrials.gov |
| NCT number | NCT07924891 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Enrollment | 6,000 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | ClinicalTrials.gov |
| Conditions | Whole-Body MRI Imaging Phenotypes | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Annualized change in mean vertebral bone marrow fat fraction | From the first eligible MRI to subsequent clinically indicated repeat MRI examinations; intervals vary by participant. Retrospective records: Jan 2015-Aug 2026; prospective observation: through Aug 31, 2030. | Vertebral bone marrow fat fraction will be measured from water-fat MRI within independently validated marrow regions of interest (ROIs), excluding cortical bone and non-marrow soft tissue. A single value is the arithmetic mean across the prespecified vertebral marrow ROIs, using the same vertebral levels in each paired examination. Annualized change is the later mean minus the earlier mean, divided by the elapsed time in years. The reported unit is percentage points/year. Only quality-controlled paired measurements are included. | ClinicalTrials.gov |
| Primary | Annualized change in visceral adipose tissue volume | From the first eligible MRI to subsequent clinically indicated repeat MRI examinations; intervals vary by participant. Retrospective records: Jan 2015-Aug 2026; prospective observation: through Aug 31, 2030. | Whole-body MRI with automated or semiautomated visceral adipose tissue segmentation and manual quality review. For each eligible pair of MRI examinations, annualized change is calculated as the later value minus the earlier value, divided by the elapsed time in years. The reported unit is L/year. Only paired measurements passing phenotype-specific quality control are included. | ClinicalTrials.gov |
| Primary | Annualized change in skeletal muscle volume | From the first eligible MRI to subsequent clinically indicated repeat MRI examinations; intervals vary by participant. Retrospective records: Jan 2015-Aug 2026; prospective observation: through Aug 31, 2030. | Whole-body MRI with automated or semiautomated skeletal muscle segmentation and manual quality review. For each eligible pair of MRI examinations, annualized change is calculated as the later value minus the earlier value, divided by the elapsed time in years. The reported unit is L/year. Only paired measurements passing phenotype-specific quality control are included. | ClinicalTrials.gov |
| Secondary | Repeatability of mean vertebral bone marrow fat fraction assessed by intraclass correlation coefficient | At repeat quantification of the same eligible MRI dataset in the measurement-validation subset; no additional scan or participant visit. | The absolute-agreement intraclass correlation coefficient (ICC) will quantify agreement between independent repeated measurements of mean vertebral bone marrow fat fraction from the same MRI dataset in the measurement-validation subset. Water-fat MRI within independently validated vertebral marrow regions of interest (ROIs), excluding cortical bone and non-marrow soft tissue. A single participant-level value is the arithmetic mean across the prespecified vertebral marrow ROIs. The same vertebral levels must contribute to both examinations. The underlying measurement is expressed in percent (%). The reported outcome is one ICC for this phenotype, without units. A value closer to 1 indicates better agreement. Longitudinal biological change between scans separated by months or years is not used as a measure of measurement repeatability. | ClinicalTrials.gov |
| Secondary | Time to death from any cause | From the first eligible MRI to the event or last available follow-up, as applicable, through August 31, 2030; observation duration varies by participant. | This outcome is the elapsed time in days from the index MRI to death from any cause. Death status and date will be ascertained from electronic medical records and available routine follow-up information, including clinical confirmation where necessary. Participants not known to have died will be censored at the last date they were known to be alive or August 31, 2030, whichever occurs first. Participants with unknown vital status will not be assumed alive through study completion. The reported unit is days. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)